TY - JOUR T1 - Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared to Delta variant in the Netherlands, 13 – 26 December 2021 JF - medRxiv DO - 10.1101/2022.01.18.22269217 SP - 2022.01.18.22269217 AU - Jantien A. Backer AU - Dirk Eggink AU - Stijn P. Andeweg AU - Irene K. Veldhuijzen AU - Noortje van Maarseveen AU - Klaas Vermaas AU - Boris Vlaemynck AU - Raf Schepers AU - Susan van den Hof AU - Chantal B.E.M. Reusken AU - Jacco Wallinga Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/28/2022.01.18.22269217.abstract N2 - The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant, due to higher transmissibility, immune evasion, or a shorter serial interval. Using S-gene target failure (SGTF) as indication for Omicron BA.1, we identify 908 SGTF and 1621 non-SGTF serial intervals in the same period. Within households, we find that the mean serial interval for SGTF cases is 0.2-0.6 days shorter than for non-SGTF cases. This suggests that the growth advantage of Omicron is partly due to a shorter serial interval.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was financed by the Netherlands Ministry of Health, Welfare and Sport. This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (grant agreement number 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise at the RIVM assessed the research proposal following the specific conditions as stated in the law for medical research involving human subjects (WMO). In their opinion the research does not fulfill one or both of these conditions and therefore conclude it is exempted for further approval by the ethical research committee. Pathogen surveillance is a legal task of the RIVM (artikel 3 Wet RIVM, article 3 Law RIVM) and is carried out under the responsibility of the Minister of Health, Welfare and Sports (VWS). Article 6c (artikel 6c) of the Public Health Act (Wet Publieke Gezondheid) provides that RIVM may receive pseudonymised data for this task without individual consent of each case. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -